Lookup NU author(s): Dr Patrick Walsh,
Dr Sally Johnson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article). All rights reserved. Haemolytic uraemic syndrome (HUS), comprising microangiopathic haemolytic anaemia, thrombocytopaenia and acute kidney injury, remains the leading cause of paediatric intrinsic acute kidney injury, with peak incidence in children aged under 5 years. HUS most commonly occurs following infection with Shiga toxin-producing Escherichia coli (STEC-HUS). Additionally, HUS can occur as a result of inherited or acquired dysregulation of the alternative complement cascade (atypical HUS or aHUS) and in the setting of invasive pneumococcal infection. The field of HUS has been transformed by the discovery of the central role of complement in aHUS and the dawn of therapeutic complement inhibition. Herein, we address these three major forms of HUS in children, review the latest evidence for their treatment and discuss the management of STEC infection from presentation with bloody diarrhoea, through to development of fulminant HUS.
Author(s): Walsh PR, Johnson S
Publication type: Article
Publication status: Published
Journal: Archives of Disease in Childhood
Online publication date: 19/02/2018
Acceptance date: 07/08/2017
ISSN (print): 0003-9888
ISSN (electronic): 1468-2044
Publisher: BMJ Publishing Group
Altmetrics provided by Altmetric